ArticleClinical and translational radiation oncology2027
Advancing brachytherapy: The GEC-ESTRO strategic vision.
Article in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Brachytherapy (BT) is an established and highly effective component of modern radiotherapy, offering a favourable therapeutic ratio for several tumor sites. Despite technological advances and strong clinical evidence, its use has declined in some countries. The GEC-ESTRO Committee of ESTRO therefore initiated a strategic process to promote and strengthen BT within European radiation oncology. Methods: The BT Think Tank (B3T), established in September 2024, comprised eight European BT specialists supported by ESTRO staff. Through structured discussions, topic prioritisation and feedback from the GEC-ESTRO Committee, key barriers to the wider implementation and promotion of BT were identified and strategic actions developed. Results: Five major areas were identified: communication, scientific research, training, reimbursement and technical development. Communication was ranked as the highest priority. Particular emphasis was placed on improving communication with patients, referring and non-BT specialists, other scientific societies, industry and healthcare stakeholders. To implement this strategy, five communication work packages were established addressing patients, other scientific societies, social media, industry, and healthcare administration/insurance. Specific milestones and activities were defined through 2028. In parallel, ongoing initiatives address clinical research, including prospective trials and real-world evidence, structured training programmes such as the EuroBT Fellowship, reimbursement analyses, and evaluation of technical developments. Conclusion: The GEC-ESTRO strategic vision aims to reposition BT as an integral component of personalised, value-based radiotherapy within the overarching strategy of ESTRO. Strengthening communication and interdisciplinary collaboration, alongside continued investment in research, training and advocacy, is essential to ensure that BT is considered as a treatment option for appropriate patients and remains accessible in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.